Trial Radar AI
Clinical Trial NCT07423143 (MISSION-O) for Menopause, Opportunistic Salpingectomy is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

Menopausal Impact of Opportunistic Salpingectomy for Ovarian Cancer Prevention (MISSION-O) 2,100 Prevention

Not yet recruiting
Clinical Trial NCT07423143 (MISSION-O) is an interventional study for Menopause, Opportunistic Salpingectomy and is currently not yet recruiting. Enrollment is planned to begin on 1 March 2026 and continue until the study accrues 2,100 participants. Led by Umeå University, this study is expected to complete by 1 December 2057. The latest data from ClinicalTrials.gov was last updated on 20 February 2026.
Brief Summary
The goal of this clinical trial is to find out whether removing the fallopian tubes at the time of hysterectomy leads to an earlier menopause. The study includes women under 55 years of age who previously underwent hysterectomy as participants in the HOPPSA trial, where they were randomly assigned to either removal of the fallopian tubes or no removal.

The main question is:

• Does removing the fallopian tubes at th...

Show More
Detailed Description
Opportunistic salpingectomy, defined as removal of the fallopian tubes during gynaecologic surgery performed for another indication, has been proposed as a strategy to reduce the risk of ovarian cancer. This approach is supported by accumulating evidence that many high-grade serous ovarian cancers originate in the distal fallopian tube. Although short-term surgical safety has been evaluated in randomized and observat...Show More
Official Title

Menopausal Impact of Opportunistic Salpingectomy for Ovarian Cancer Prevention

Conditions
MenopauseOpportunistic Salpingectomy
Publications
Scientific articles and research papers published about this clinical trial:
Other Study IDs
  • MISSION-O
  • MISSION-O-26
  • 2024-06333 (Other Grant/Funding Number) (The Swedish Research Council)
  • RV-1004811 (Other Grant/Funding Number) (Region Västerbotten)
  • Dnr. 2025-08086-01 (Other Identifier) (The Swedish Ethical Review Authority)
NCT ID Number
NCT07423143
Start Date (Actual)
2026-03
Last Update Posted
2026-02-20
Completion Date (Estimated)
2057-12
Enrollment (Estimated)
2,100
Study Type
Interventional
PHASE
N/A
Status
Not yet recruiting
Keywords
opportunistic salpingectomy
hysterectomy
nested trial
randomised controlled trial
RCT
follicle-stimulating hormone
self-sampling
dried blood spot cards
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
Double
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalOpportunistic salpingectomy
Salpingectomy at the time of hysterectomy for a benign reason
Opportunistic Salpingectomy
Removal of the fallopian tubes at the time of hysterectomy
No InterventionNo salpingectomy
No salpingectomy at hysterectomy for a benign reason
N/A
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Age at menopause
Evaluated using serum follicle-stimulating hormone (FSH) levels analysed in self-sampled dried blood spots. Continuous outcome measured in years. Samples collected twice one year apart.
1 year
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Cardiovascular disease - CVD
Dichotomous outcome. Diagnosis will be classified according to ICD-10. Data from national health registers will be retrieved. The outcome will be further described according to types of cardiovascular disease, i.e. coronary heart disease and stroke, as well as age at CVD.
10-30 years after enrolment.
Mortality
Dichotomous outcome, the diagnosis is classified according to ICD-10. Data retrieved from the national Cause of Death Register. Mortality will be further described as all-cause mortality, and mortality due to cardio-vascular disease.
10-30 years after enrolment.
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
20 Years
Eligible Sexes
Female
  • Having had hysterectomy for a benign indication
  • Less than 55 years at surgery
  • Was included in the ITT population of the HOPPSA register-based randomised controlled trial (R-RCT) of opportunistic salpingectomy
  • Informed consent

  • Ongoing systemic hormonal treatment using sex steroids
  • Bilateral oophorectomy
  • Cancer treatment affecting ovarian function
  • Other treatments with major effects on ovarian function
Umeå University logoUmeå University106 active studies to explore
Study Central Contact
Contact: Annika Idahl, MD, PhD, Professor, +46 90 786 73 18, [email protected]
Contact: Camilla Ersviken, Trial coordinator, [email protected]
1 Study Locations in 1 Countries
Umeå University, Umeå, 90346, Sweden
Sara Knip, MD, Contact, [email protected]
Marja-Liisa L Tafvelin, MSc, Contact, [email protected]